Gland Pharma Limited Stock Price Today (NSE: GLAND)
Fundamental Score
Gland Pharma Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Gland Pharma Limited share price today is ₹2826.60, down 2.38% on NSE/BSE as of 16 September 2026. Gland Pharma Limited (GLAND) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹46.63K (Cr). The 52-week high for GLAND share price is ₹3042.00 and the 52-week low is ₹1573.60. At a P/E ratio of 41.26x, GLAND is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 10.53% and a debt-to-equity ratio of 0.02.
Gland Pharma Limited Share Price Chart — NSE/BSE Historical Performance
Gland Pharma Limited share price chart: 10.95% return over the past month. 52-week high ₹3042.00, 52-week low ₹1573.60.
Gland Pharma Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹2877.00 | ₹2914.20 | ₹2792.40 | ₹2826.60 | 7.49L (Cr) | |
| ₹2930.00 | ₹2940.00 | ₹2856.90 | ₹2895.50 | 4.98L (Cr) | |
| ₹2940.00 | ₹2950.10 | ₹2882.00 | ₹2922.30 | 3.89L (Cr) | |
| ₹3031.00 | ₹3031.00 | ₹2918.90 | ₹2946.90 | 3.69L (Cr) | |
| ₹2959.30 | ₹3033.90 | ₹2938.60 | ₹3026.20 | 15.61L (Cr) | |
| ₹2979.90 | ₹2979.90 | ₹2901.90 | ₹2959.30 | 7.10L (Cr) | |
| ₹2929.60 | ₹3042.00 | ₹2916.90 | ₹2974.30 | 10.31L (Cr) | |
| ₹2915.00 | ₹2969.00 | ₹2851.10 | ₹2932.40 | 29.78L (Cr) | |
| ₹2870.00 | ₹2948.00 | ₹2847.60 | ₹2907.90 | 1.89L (Cr) | |
| ₹2915.00 | ₹2930.00 | ₹2803.00 | ₹2868.40 | 5.56L (Cr) |
Gland Pharma Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹2885.70 | ₹3042.00 | ₹2792.40 | ₹2826.60 | -2.05% | |
| ₹2505.60 | ₹3039.80 | ₹2494.10 | ₹2885.80 | +15.17% | |
| ₹2495.00 | ₹2586.00 | ₹2360.00 | ₹2502.90 | +0.32% | |
| ₹2278.60 | ₹2528.30 | ₹2167.80 | ₹2495.00 | +9.50% | |
| ₹1750.80 | ₹2396.00 | ₹1748.00 | ₹2250.00 | +28.51% | |
| ₹1701.70 | ₹1832.00 | ₹1652.00 | ₹1750.80 | +2.89% | |
| ₹1780.00 | ₹1802.10 | ₹1573.60 | ₹1696.10 | -4.71% | |
| ₹1815.80 | ₹1984.90 | ₹1748.90 | ₹1822.20 | +0.35% | |
| ₹1716.60 | ₹1874.80 | ₹1650.00 | ₹1846.60 | +7.57% | |
| ₹1768.20 | ₹1815.00 | ₹1629.60 | ₹1722.00 | -2.61% | |
| ₹1942.70 | ₹2034.00 | ₹1730.00 | ₹1759.60 | -9.43% | |
| ₹1992.00 | ₹2026.10 | ₹1889.00 | ₹1928.90 | -3.17% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Gland Pharma Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Gland Pharma Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of GLAND across key market metrics for learning purposes.
Positive Indicators
11 factors identified
Strong Operating Margins (29.53%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (47.09%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (19.57%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (13.18% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Conservative Debt Levels (D/E: 0.02)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (45.01x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 4.33)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Cash Generation (₹2069.23 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (51.83%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Strong Institutional Confidence (FII+DII: 40.65%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Premium Valuation Risk (P/E: 41.26x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
High Price-to-Book Ratio (5.09x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Weak Earnings Growth (-0.23% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (0.60% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Gland Pharma Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Gland Pharma Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Gland Pharma LimitedGland Pharma Li...Selected✓ GLAND • 543245 | 61.2/100 | ₹2826.60₹2827 | ₹46627.59₹46627.59 | 41.26Average 41.3 Average | 10.53%Average 10.53% Average | 14.57%Average 14.57% Average | 0.02Excellent 0.0 Excellent | 0.60%Average 0.60% Average | 13.18%Good 13.18% Good | 0.81% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1876.50₹1877 | ₹450228.65₹450228.65 | 37.23Average 37.2 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9467.50₹9468 | ₹250888.75₹250888.75 | 85.90Average 85.9 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4939.50₹4940 | ₹167182.32₹167182.32 | 78.91Average 78.9 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1138.70₹1139 | ₹113642.26₹113642.26 | 25.38Average 25.4 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1371.90₹1372 | ₹110828.94₹110828.94 | 32.87Average 32.9 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1941.10₹1941 | ₹104867.93₹104867.93 | 95.81Average 95.8 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1683.00₹1683 | ₹96839.82₹96839.82 | 26.30Average 26.3 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.70₹2101 | ₹96054.51₹96054.51 | 17.36Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1144.50₹1145 | ₹95565.75₹95565.75 | 29.58Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2293.70₹2294 | ₹94729.81₹94729.81 | 46.35Average 46.3 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price450228.65 Cr
- Divi's Laboratories Limited share price250888.75 Cr
- Torrent Pharmaceuticals Limited share price167182.32 Cr
- Zydus Lifesciences Limited share price113642.26 Cr
- Cipla Limited share price110828.94 Cr
Gland Pharma Limited PE Ratio History
Historical price-to-earnings ratio for GLAND — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹42.40 | ₹1722.00 | 40.6x |
| FY 2024 | ₹46.89 | ₹1779.35 | 37.9x |
| FY 2023 | ₹47.43 | ₹1924.50 | 40.6x |
| FY 2022 | ₹73.64 | ₹1576.55 | 21.4x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Gland Pharma Limited Dividend History
Annual cash dividends paid by GLAND — dividend yield 0.81%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹329.49 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Gland Pharma Limited Quarterly Performance
Latest quarterly metrics for GLAND — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
19.57%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
47.09%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
13.18%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
0.60%
Compounded annual net profit growth over 5 years
Gland Pharma Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for GLAND — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Gland Pharma Limited Financial Statements
Annual income statement, balance sheet and cash flow for Gland Pharma Limited (GLAND) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Gland Pharma Limited
About GLAND (Gland Pharma Limited)
Gland Pharma Ltd is a global pharmaceutical powerhouse specializing in sterile injectables, a critical and complex field requiring precision and expertise. They develop, manufactur...e, and market a diverse range of injectable products, catering to various therapeutic areas and dosage forms. The company distinguishes itself through its commitment to quality and regulatory compliance, adhering to stringent international standards across its facilities. From vials and ampoules to pre-filled syringes and lyophilized products, Gland Pharma offers a comprehensive portfolio to meet the evolving needs of healthcare providers and patients worldwide. Their expansive geographical reach ensures that vital medications are accessible to communities across the globe, solidifying their position as a trusted provider of essential injectable pharmaceuticals. Beyond its manufacturing capabilities, Gland Pharma also invests significantly in research and development, with a focus on developing innovative injectable formulations and enhancing existing products. They are actively involved in the development of complex molecules, including peptides and biosimilars, signaling a forward-thinking approach to address unmet medical needs. This commitment to innovation extends to exploring novel drug delivery systems and formulations that improve patient outcomes and reduce healthcare costs. By combining its robust manufacturing infrastructure with a dynamic R&D pipeline, Gland Pharma is strategically positioned to capitalize on emerging opportunities in the global injectable market and maintain its competitive edge in the long term. This positions them as more than just a manufacturer, but an innovator in the space. Gland Pharma’s success is underpinned by a strong foundation of technical expertise, quality control systems, and a customer-centric approach. The company fosters a culture of continuous improvement, constantly seeking ways to optimize its processes and enhance the value it delivers to its partners. Their commitment to sustainability is evident in their environmentally conscious manufacturing practices and responsible sourcing of raw materials. This dedication to ethical and sustainable practices aligns with the growing demand for responsible corporate citizenship within the pharmaceutical industry. Ultimately, Gland Pharma strives to be a reliable and trusted partner, delivering high-quality injectable medications that improve the lives of patients around the world.
Company Details
Key Leadership
GLAND Share Price: Frequently Asked Questions
What is the current share price of Gland Pharma Limited?
Gland Pharma Limited (GLAND) trades at ₹2826.60 on NSE and BSE. Market cap ₹46.63K (Cr). Educational data only.
What is the P/E ratio of Gland Pharma Limited?
Gland Pharma Limited has a P/E of 41.26x vs industry average 34.89x.
What is the Bull Run score for Gland Pharma Limited?
Gland Pharma Limited has a Bull Run score of 61.2/100 based on 25+ financial parameters.
Does Gland Pharma Limited pay dividends?
Gland Pharma Limited has a dividend yield of 0.81%. Past dividends don't guarantee future payments.
What is the ROE of Gland Pharma Limited?
Gland Pharma Limited has ROE of 10.53%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Gland Pharma Limited?
Gland Pharma Limited has debt-to-equity of 0.02.
Is Gland Pharma Limited a good investment?
Bull Run gives Gland Pharma Limited a score of 61.2/100. This is not investment advice — consult a SEBI-registered advisor.